机器人辅助对比传统微创食管切除术治疗可切除食管鳞癌:RAMIE 试验早期结果
RAMIE 试验为前瞻性多中心随机对照研究,纳入中国 6 家中心可切除食管鳞癌患者,比较机器人辅助微创食管切除术(RAMIE)与常规微创食管切除术(MIE)。结果显示 RAMIE 手术时间更短,新辅助治疗患者胸腔淋巴结清扫数目更多,左侧喉返神经旁淋巴结清扫完成率更高,两组并发症与 90 天死亡率无差异。
要点
- RAMIE 手术时间显著短于 MIE(203.8 vs 244.9 分钟)。
- 新辅助治疗患者中 RAMIE 胸腔淋巴结清扫数目更多(15 vs 12)。
- 两组总体并发症、主要并发症及 90 天死亡率无显著差异。
核心结论
- RAMIE 与 MIE 治疗食管鳞癌均安全可行,RAMIE 可缩短手术时间并改善新辅助治疗患者的淋巴结清扫。
研究设计与样本
- 前瞻性多中心随机对照试验,2017 年 8 月至 2019 年 12 月在中国 6 家高容量中心纳入可切除食管鳞癌患者,随机接受 RAMIE 或 MIE,采用意向性治疗分析。
主要发现
- RAMIE 手术时间显著短于 MIE(203.8 vs 244.9 分钟,P<0.001)。
- 接受新辅助治疗患者中,RAMIE 胸腔淋巴结清扫数目多于 MIE(15 vs 12,P=0.016)。
- RAMIE 左侧喉返神经旁淋巴结清扫完成率高于 MIE(79.5% vs 67.6%,P=0.001)。
- 两组出血量、中转率及 R0 切除率无差异,90 天死亡率均为 0.6%。
- 总体并发症(48.6% vs 41.8%,RR 1.16,95%CI 0.92-1.46,P=0.196)及主要并发症(12.2% vs 10.2%,P=0.551)无显著差异。
关键数值与推荐
- 总体并发症 RAMIE 48.6% 对比 MIE 41.8%(RR 1.16,95%CI 0.92-1.46,P=0.196)。
- 主要并发症(Clavien-Dindo≥III)RAMIE 12.2% 对比 MIE 10.2%(P=0.551)。
- 肺部并发症 RAMIE 13.8% 对比 MIE 14.7%(P=0.812)。
- 吻合口漏 RAMIE 12.2% 对比 MIE 11.3%(P=0.801)。
- 声带麻痹 RAMIE 32.6% 对比 MIE 27.1%(P=0.258)。
临床怎么用
- RAMIE 可作为可切除食管鳞癌的微创手术选择之一,尤其在新辅助治疗后需精细淋巴结清扫的患者中可能获益。
- 选择术式时需结合中心经验与设备条件,RAMIE 与 MIE 在短期安全性上总体相当。
局限性
- 本文报告的是早期结果,长期疗效尚待进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare perioperative and long-term outcomes of robot-assisted minimally invasive esophagectomy (RAMIE) and conventional minimally invasive esophagectomy (MIE) in the treatment for patients with esophageal squamous cell carcinoma (ESCC). SUMMARY BACKGROUND DATA: RAMIE has emerged as an alternative to traditional open or thoracoscopic approaches. Efficacy and safety of RAMIE and MIE in the surgical treatment for ESCC remains uncertain given the lack of high-level clinical evidence. METHODS: The RAMIE trial was designed as a prospective, multicenter, randomized, controlled clinical trial that compares the efficacy and safety of RAMIE and MIE in the treatment of resectable ESCC. From August 2017 to December 2019, eligible patients were randomly assigned to receive either RAMIE or MIE performed by experienced thoracic surgeons from 6 high-volume centers in China. Intent-to-treat analysis was performed. RESULTS: Significantly shorter operation time was taken in RAMIE (203.8 vs 244.9 min, P<0.001). Compared with MIE, RAMIE showed improved efficiency of thoracic lymph node dissection in patients who received neoadjuvant therapy (15 vs 12, P = 0.016), as well as higher achievement rate of lymph node dissection along the left recurrent laryngeal nerve (79.5% vs 67.6%, P = 0.001). No difference was found in blood loss, conversion rate, and R0 resection. The 90-day mortality was 0.6% in each group. Overall complications were similar in RAMIE (48.6%) compared with MIE (41.8%) (RR, 1.16; 95% CI, 0.92-1.46; P = 0.196). Besides, the rate of major complications (Clavien-Dindo classification ≥ III) was also comparable (12.2% vs 10.2%, P = 0.551). RAMIE showed similar incidences of pulmonary complications (13.8% vs 14.7%; P = 0.812), anastomotic leakage (12.2% vs 11.3%; P = 0.801), and vocal cord paralysis (32.6% vs 27.1%, P = 0.258) to MIE. CONCLUSIONS: Early results demonstrate that both RAMIE and MIE are safe and feasible for the treatment of ESCC. RAMIE can achieve shorter operative duration and better lymph node dissection in patients who received neoadjuvant therapy. Long-term results are pending for further follow-up investigations. TRIAL REGISTRATION: ClinicalTrial.gov Identifier: NCT03094351.
引用
- Yang Y, Li B, Yi J, et al. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial. Ann Surg. 2022. PMID: 34171870. doi:10.1097/SLA.0000000000005023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。